FDA Brief

Warning letters Devices

FDA warning letter to

Palamur Biosciences Private Limited

High riskIssued Dec 11, 2025Posted Dec 30, 2025Center for Devices and Radiological Health

FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.

What happened

FDA inspected Palamur Biosciences from January 20, 2025, to January 27, 2025, and reviewed Good Laboratory Practice (GLP) nonclinical studies for medical devices, including implantation, acute systemic toxicity, material-mediated pyrogenicity, guinea pig maximization, intracutaneous reactivity, and in vitro cytotoxicity. The inspection found incomplete and unverifiable study records, inadequate standard operating procedures, training gaps, and missed quality-assurance review, and FDA said the company’s responses were inadequate. FDA also cited a blood-sample record issue in an animal drug study and dirt, animal droppings, and possible pest harborage outside the facility.

What FDA found

  1. The study director did not ensure all study data were accurately recorded and verified, including animal ages, IV injection rate and time, and physical exams.

    21 CFR 58.33(b)
  2. The testing facility lacked adequate written standard operating procedures for balance calibration, device extract preparation, and CO2 euthanasia.

    21 CFR 58.81(a)
  3. Management did not ensure staff clearly understood their duties, and staff failed to record adverse tissue responses and clinical signs in a guinea pig study.

    21 CFR 58.31(f)
  4. The quality assurance unit did not catch an unauthorized protocol deviation in which an endotracheal tube was used instead of the planned supraglottic airway device.

    21 CFR 58.35(b)(5)
  5. In an animal drug study, records showed most blood samples were centrifuged before collection, and the company could not reconstruct what happened.

  6. FDA observed significant dirt, animal droppings, and possible pest harborage outside the facility, including near HVAC equipment.

What FDA wants

Within 15 working days, provide documentation of corrective and preventive actions, projected completion dates, and a plan to monitor effectiveness, plus a list of all FDA-regulated device nonclinical studies for the last five years.

Who should pay attention

  • medical device manufacturers relying on this lab for biocompatibility or toxicology testing
  • sponsors of premarket submissions that use these GLP studies
  • companies using this lab for animal drug studies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Online Generic Medicine/www.onlinegenericmedicine.com

    FDA warned Online Generic Medicine that its website sells unapproved, misbranded injectable semaglutide to U.S. consumers.

    High risk
  3. BioDrive, Inc.

    FDA warned BioDrive that its Evolv GLP-1 Biomimetic dietary supplement is adulterated over the new dietary ingredient EV1-Peptide and safety concerns.

    High risk
  4. Peak Performance Peptides

    Peak Performance Peptides sold unapproved injectable peptide drugs, including semaglutide and retatrutide, without FDA approval.

    High risk